? CORE A (ADMINISTRATION) The overall objective of Administrative Core A is to provide all scientists collaborating on this multi-institutional Program Project a chance to form a synergistic team by facilitating the interaction among Project and Core Leaders, research administration at the parent institution, the Texas Biomedical Research Institute (Texas Biomed)/Southwest National Primate Research Center (SNPRC) and at the affiliated institutions, as well as NIH representatives. The network of collaborating scientists includes researchers in the Northeast, Midwest and Southwest of the United States and extends to Europe.
The Specific Aims of Core A are to: 1. provide administrative support to facilitate the collaboration among all Project, Core and Subcontract Leaders, including the exchange of information, reagents, and Material Transfer Agreements (MTAs); 2. set scientific priorities, monitor overall progress, and evaluate the timely achievement of scientific milestones. This will be achieved with the participation of the Internal Steering Committee (ISC) and regular input from the External Scientific Advisory Board (ESAB) and the NIAID Program Officer. The ISC includes all Project and Core Leaders/Co-Leaders as well Drs. Sarah Ratcliffe (Biostatistician); 3. assist in the exchange of experimental rhesus macaques between the SNPRC and the Research Imaging Institute (RII) of the University of Texas Health Science Center at San Antonio (UTHSCSA); 4. provide statistical support for all Program Project scientists through the participation of Dr. Sarah Ratcliffe (Subcontract with the University of Pennsylvania); 5. provide financial oversight and to assure the timely achievement of the experimental goals within the budget limits; 6. organize the yearly site visit and ESAB meeting as well as individual visits of Drs. Tom Hope, Darrell Irvine or their colleagues to San Antonio; 7. address intellectual property (IP) issues in a timely and equitable way; 8. facilitate timely completion of reports, dissemination of data at meetings, and publication of manuscripts. To achieve these objectives, the Core A Leader/P.I. depends on the support of trained professionals with excellent organizational skills and the ability to handle shipment of infectious agents.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Louisiana at Lafayette
United States
Zip Code
Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527
Ruprecht, Ruth M; Lakhashe, Samir K (2017) Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS 12:222-228
Ruprecht, Ruth M (2017) Anti-HIV Passive Immunization: New Weapons in the Arsenal. Trends Microbiol 25:954-956
Schneider, Jeffrey R; Carias, Ann M; Bastian, Arangaserry R et al. (2017) Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods 450:66-72
Kulkarni, Viraj; Ruprecht, Ruth M (2017) Mucosal IgA Responses: Damaged in Established HIV Infection-Yet, Effective Weapon against HIV Transmission. Front Immunol 8:1581
Sholukh, Anton M; Watkins, Jennifer D; Vyas, Hemant K et al. (2015) Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:2086-95
Lakhashe, Samir K; Byrareddy, Siddappa N; Zhou, Mingkui et al. (2014) Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine 32:6527-36
Zhou, Mingkui; Ruprecht, Ruth M (2014) Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109
Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan et al. (2014) Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 11:8
Bachler, Barbara C; Humbert, Michael; Lakhashe, Samir K et al. (2013) Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology 10:63

Showing the most recent 10 out of 77 publications